Assertio Therapeutics Company Analysis and Investment Insights

Assertio Therapeutics is a pharmaceutical company that has made significant strides in the industry. The company was founded in 2013 by former executives of Depomed, a pharmaceutical company that was acquired by Mallinckrodt in 2014.

Assertio Therapeutics has a portfolio of products that include opioids, pain management medications, and other specialty pharmaceuticals. Their product portfolio is a key factor in their success.

Assertio Therapeutics has a strong presence in the market, with a significant number of employees and a strong distribution network. This has enabled them to effectively reach a wide customer base.

Assertio Therapeutics' revenue has been increasing steadily over the years, driven by the growth of their product portfolio and the expansion of their distribution network.

For another approach, see: Goggo Network

Assertio Therapeutics has a clear focus on advancing patient care in its core areas of neurology, orphan, and specialty medicines. This is evident from its mission statement, which emphasizes its commitment to providing responsible solutions to improve patient outcomes.

The company has a strong product portfolio, with three FDA-approved products currently on the market. Assertio is also actively identifying, licensing, and developing new products to address unmet needs in these areas.

Assertio's strategic direction is centered around its neurology, orphan, and specialty medicines, which now account for over 60% of total revenue. This shift towards high-margin products has led to a significant increase in profitability, with GAAP net income surging to $16.4 million in Q2 2025.

The company's operational efficiency and reduced overhead costs have also contributed to its improved financial performance. Assertio's adjusted EBITDA rose to $5.6 million in Q2 2025, reflecting its successful strategic realignment.

Here's a snapshot of Assertio's key financial metrics:

Assertio's focus on its core areas of expertise has enabled the company to streamline operations and redirect resources to high-growth products. This strategic pivot has been instrumental in driving its financial turnaround and positioning the company for long-term success.

Assertio Therapeutics has a market capitalization of $78.9 million, which is relatively small compared to its annual sales of $124.9 million. This suggests that the company is undervalued.

The company has a significant amount of cash on hand, with $98.2 million in cash and investments. This liquidity is further bolstered by a debt structure that includes only $40 million in convertible notes maturing in 2027.

Assertio's current ratio is 1.66, indicating that it has a strong ability to pay its short-term debts. The company has also resolved major legal liabilities, reducing future legal exposure by over 80%.

Here are some key financial metrics for Assertio Therapeutics:

The company's price-to-sales ratio is 0.63, which is lower than the industry average. This suggests that the stock is undervalued compared to its peers. Analysts have set price targets ranging from $1.50 to $3.50, implying a potential 110% to 380% upside.

Assertio Therapeutics is a company that's flying under the radar, and that's a great thing for investors. The stock trades at a significant discount to its intrinsic value, which means it's undervalued.

At $0.72 per share, the market cap of $70 million is dwarfed by the company's $98.2 million cash reserves. This is a huge advantage for the company, and it's not something you see every day.

The analysts are on board with the company's potential, setting price targets ranging from $1.50 to $3.50. This implies a potential 110% to 380% upside, which is a staggering return on investment.

The company's updated 2025 guidance is also a positive sign, with net product sales projected to reach $108–118 million and adjusted EBITDA projected to reach $11–19 million. This suggests a trajectory of consistent growth, which is exactly what investors want to see.

Assertio Therapeutics has a portfolio of prescription products that contain a range of active ingredients.

One of these active ingredients is fentanyl, a potent opioid pain medication that is often used to treat severe pain in patients with cancer or other conditions.

Fentanyl is a synthetic opioid that is approximately 50-100 times more potent than morphine, making it a highly effective pain reliever in small doses.

The company's products also contain other active ingredients such as hydromorphone, a semi-synthetic opioid that is commonly used to treat moderate to severe pain.

Hydromorphone is often used in combination with other medications to enhance its pain-relieving effects.

Other active ingredients in Assertio Therapeutics' products include gabapentin, an anticonvulsant medication that is also used to treat nerve pain.

Gabapentin has been shown to be effective in reducing the severity of nerve pain in patients with conditions such as fibromyalgia and shingles.

Assertio Therapeutics's position in the market can be a game-changer for your business development strategy. You can enhance your sales strategy and increase your chances of success by understanding their market position.

To stay ahead of the competition, keep an eye on mergers and acquisitions (M&A) activity, capital raising, and alliances and partnerships, including legal and financial adviser associations. This valuable insight can help you make informed decisions.

Here are some key areas to focus on:

Assertio Therapeutics, a small cap company, saw its shares drop by over 18% after announcing a settlement in a patent infringement dispute with Purdue Pharma. The company will receive a total of $62 million.

The settlement amount was lower than what analysts were expecting. This has raised concerns about the company's financial stability.

Assertio Therapeutics exited June 2018 with $57 million in cash and cash equivalents. The company reported a net loss of $21 million during that quarterly period.

The company's operating cash flow was negative $14 million for the first half of the year. This indicates that the company is struggling to generate cash from its operations.

The settlement payment will be received in two installments, with $32 million paid this week and the remaining $30 million due in February 2019.

Business Development is all about staying ahead of the game. To enhance your sales strategy and increase your chances of success, it's essential to understand your position in the market and identify potential areas for collaboration.

Assertio Therapeutics is a company you might want to keep an eye on. Understanding their position in the market can help you identify potential areas for collaboration.

Staying ahead of your competitors is crucial in business. Valuable insights on mergers and acquisitions (M&A) activity, capital raising, and alliances and partnerships can give you a competitive edge.

Here are some key areas to focus on:

Knowing who's behind the company can also be helpful. Assertio Therapeutics's key executives are worth identifying and researching.